The rising stock market had many winners on Wednesday, but alas for its shareholders FibroGen (NASDAQ: FGEN) wasn't one of them. Goldman Sachs analyst Paul Choi has downshifted his recommendation for FibroGen stock. Choi's concern is the company's leading product, roxadustat, which targets anemia due to chronic kidney disease.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting